Profil
Doris Peterkin is the founder of OncoPep, Inc. since 2010, where she currently holds the title of Chief Executive Officer & Director.
She is also a former President & Chief Executive Officer of Healagenics, Inc.
Postes actifs de Doris Peterkin
| Sociétés | Poste | Début |
|---|---|---|
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Fondateur | 01/01/2010 |
Anciens postes connus de Doris Peterkin
| Sociétés | Poste | Fin |
|---|---|---|
Healagenics, Inc.
 Healagenics, Inc. Medical SpecialtiesHealth Technology Healagenics, Inc. is dedicated to developing innovative products for advanced wound care that have the potential to help people every day who are suffering and at risk for further serious medical complications. The company's initial product, the FDA-cleared Healadex®, is the first to use porcine serum in moist wound dressings for the treatment of acute and chronic wounds. Healagenics continues to develop groundbreaking products for both clinician use and over-the-counter sales in the treatment of wound care. Founded in 2006, Healagenics is a privately-held biomedical technology company headquartered in Woburn, Massachusetts. | President | 17/01/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Finance |
Healagenics, Inc.
Healagenics, Inc. Medical SpecialtiesHealth Technology Healagenics, Inc. is dedicated to developing innovative products for advanced wound care that have the potential to help people every day who are suffering and at risk for further serious medical complications. The company's initial product, the FDA-cleared Healadex®, is the first to use porcine serum in moist wound dressings for the treatment of acute and chronic wounds. Healagenics continues to develop groundbreaking products for both clinician use and over-the-counter sales in the treatment of wound care. Founded in 2006, Healagenics is a privately-held biomedical technology company headquartered in Woburn, Massachusetts. | Health Technology |
